Archon
Seattle, US · 27 employees on LinkedIn · 3 known investors
Find your way into Archon
5 people in our graph share verified history with the Archon team — schools, employers, funds. One of them is your warm intro.
Chris Picardounlockedknows James Lazarovits · together at Archon (overlapped)
×3knows the team · via Institute for Protein Design, University of Washington
knows the team · via Archon
Archon Biosciences develops a computational protein design platform leveraging AI and deep learning for therapeutic and vaccine applications. The company was founded in 2023 by James Lazarovits and George Ueda, Ph.D., building on research in AI-driven protein engineering and nanomaterial delivery.
Founders & leadership
GU
George Ueda, Ph.D.Chief Technology Officer, Co-Founder
JL
James Lazarovits, Ph.D.Chief Executive Officer, Co-Founder
JL
James LazarovitsinCo-Founder and CEOBiomedical engineer with background in software, hardware, and robotics startups and investment, now co-founder of Archon Biosciences, which develops AI-driven protein design technology for therapeutic and vaccine applications.
GU
George UedainCo-Founder and CTO
Investors · 3
Competitors · 3
by search overlapCreyon18 shared keywordsCreyon develops aptamer-delivered oligonucleotide therapeutics for targeted cell-specific delivery, including small interfering RNA and antisense oligonucleotides. The company's platform addresses limitations in tissue penetration and immunogenicity for central nervous system and other tissue-targeted applications.
Regeneron NASDAQ: REGN www.regeneron.com17 shared keywordsRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
Orca Bio17 shared keywordsOrca Bio develops allogeneic T-cell immunotherapies for high-risk blood cancers including acute myeloid leukemia, acute lymphocytic leukemia, and myelodysplastic syndrome. The company is advancing precision cell therapy treatments for patients with blood cancers and autoimmune diseases.
Companies competing with Archon for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Archon do?
- Archon Biosciences develops a computational protein design platform leveraging AI and deep learning for therapeutic and vaccine applications. The company was founded in 2023 by James Lazarovits and George Ueda, Ph.D., building on research in AI-driven protein engineering and nanomaterial delivery.
- Who founded Archon?
- Archon was founded by George Ueda, Ph.D., James Lazarovits, Ph.D., James Lazarovits, George Ueda.
- Who are Archon's investors?
- Archon's investors include Cornucopian Capital Management, Madrona Venture Group, Y Combinator.
- Where is Archon headquartered?
- Archon is headquartered in Seattle, US.